GlassScriptPhysician profile
Jalaj Garg
NPI 1558631663
$88,520.22
in general payments reported to CMS, 2019-2025
19 companies · $10K in 2025
The $10K reported for 2025 was more than what 81% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,794 · 2021: $3,277 · 2022: $23K · 2023: $34K · 2024: $16K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Honoraria: $8,589 · Travel and Lodging: $8,386 · Food and Beverage: $5,933 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,475.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,785.00 |
| Honoraria | $8,589.00 |
| Travel and Lodging | $8,386.40 |
| Food and Beverage | $5,933.02 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23,738.83 | 2021-2025 | Micra, Mycarelink, Azure Xt Dr Mri Surescan |
| Atricure, INC. | $18,571.47 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8,739.57 | 2023-2025 | Lifevest |
| Medical Device Business Services, INC. | $8,550.00 | 2023-2024 | Carto 3 |
| Biosense Webster, INC. | $7,256.63 | 2021-2025 | Carto 3, Thermocool Sf, Qdot Micro Catheter |
| Biotronik INC. | $6,918.21 | 2021-2023 | Edora 8 Dr-T, Sentus, Acticor 7 Vr-T Dx |
| Altathera Pharmaceuticals LLC | $5,550.95 | 2023-2025 | Sotalol Hydrochloride |
| Abbott Laboratories | $3,199.89 | 2019-2025 | Ep-Workmate |
| Kestra Medical Technology Services, INC. | $2,674.78 | 2024-2025 | Assure Wcd |
| Boston Scientific Corporation | $1,774.41 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Access System, Emblem Mri S-Icd |
| Acutus Medical, INC. | $750.18 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $607.25 | 2023-2024 | Xarelto |
| Becton, Dickinson and Company | $58.00 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $31.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $27.09 | 2023 | Eliquis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $24.37 | 2024 | Mynx Venous Vcd |
| Medtronic Vascular, INC. | $19.34 | 2019 | |
| Irhythm Technologies, INC. | $16.58 | 2023 | Zio Xt Patch |
| Philips North America LLC | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jalaj Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.